Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 5Sarcoma 3Lymphoid 3Tumor-Agnostic 2Plasma cell 2Other hematologic neoplasm 2Gynecologic 2Gastrointestinal 2Myeloid 1

Conditions

Neoplasms 2

Interventions

pembrolizumab 95Paclitaxel 86Gemcitabine 84Carboplatin 79Surveys and Questionnaires 72Docetaxel 61Bevacizumab 61Nivolumab 59Cisplatin 59Magnetic Resonance Spectroscopy 50Blood Specimen Collection 50Fluorouracil 48Radiotherapy 47Capecitabine 47Irinotecan 40Oxaliplatin 38Erlotinib Hydrochloride 38Biopsy 36atezolizumab 35Leucovorin 35Pemetrexed 34Standard of Care 32Cetuximab 32Specimen Handling 31Trastuzumab 30Radiosurgery 29Ipilimumab 28Cyclophosphamide 28Interviews as Topic 27olaparib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tetanus Toxoid × Tumor-Agnostic × Clear all
NCT03251924 2023-02-28

A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Terminated
80 enrolled 33 charts
Tumor-Agnostic

Neoplasms

NCT00000105 2017-11-29

Vaccination With Tetanus and KLH to Assess Immune Responses.

Masonic Cancer Center, University of Minnesota

Terminated
112 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡